ABBV vs CAT: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Caterpillar Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-08.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Caterpillar Inc. · Industrials
$940.12
-39.4% upside to fair value
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
CAT trades at a lower forward P/E
(46.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
CAT |
| Current Price |
$261.07 |
$940.12 |
| Fair Value Estimate |
$264.30 |
$569.47 |
| Upside to Fair Value |
+1.2%
|
-39.4%
|
| Market Cap |
$461.3B |
$433.1B |
| Forward P/E |
128.0x
|
46.6x
|
| EV / EBITDA |
31.0x
|
29.7x
|
| Price / Sales |
7.3x
|
6.1x
|
| Price / FCF |
22.1x
|
37.8x
|
| Revenue Growth YoY |
+12.4%
|
+22.2%
|
| Gross Margin |
70.7%
|
32.5%
|
| Operating Margin |
27.6%
|
16.6%
|
| Return on Equity |
68.0%
|
47.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
2.64%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Caterpillar Inc. is a leading global manufacturer of agricultural and construction machinery, operating within the Industrials sector. The company demonstrates high business quality with a durable competitive moat supported by strong brand recognition, cost advantages, and intangible assets. It posted robust revenue growth of 22.2% and earnings growth of 27.3% in the most recent quarter, reflecti…
Accumulation Zones
| Metric |
ABBV |
CAT |
| Zone Low |
$198.23 |
$427.10 |
| Zone High |
$224.66 |
$484.05 |
| In Buy Zone? |
No
|
No
|